Affimed GmbH
Technologiepark
Im Neuenheimer Feld 582
Heidelberg
69120
Germany
Tel: 49-6221-65307-0
Fax: 49-6221-65307-77
Website: http://www.affimed.com/
Email: info@affimed.com
119 articles with Affimed GmbH
-
Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
8/4/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022.
-
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
6/10/2022
Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster at the Annual Meeting of the European Hematology Association (EHA) in Vienna, Austria.
-
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
6/1/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the first quarter ended March 31, 2022 and provided an update on clinical and corporate progress.
-
Affimed to Present at the 2022 Jefferies Healthcare Conference
5/26/2022
Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:00 p.m. Eastern Daylight Time / 19:00 Central European Time.
-
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
5/26/2022
Affimed N.V. announced that three abstracts of clinical trial designs of its AFM24 innate cell engager have been published and will be presented at the American Society of Clinical Oncology Annual Meeting, taking place on June 3-7, 2022 in Chicago, IL.
-
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022
5/24/2022
Affimed N.V. announced that it will release first quarter 2022 results and corporate update on Wednesday, June 1, 2022.
-
Affimed Announces Annual General Meeting of Shareholders - May 24, 2022
5/24/2022
Affimed N.V. announced that its 2022 Annual General Meeting of Shareholders will be held on June 22, 2022 at 09:00 a.m. CET at the Radisson Blu Hotel, Amsterdam City Center, Rusland 17, 1012 CK Amsterdam, the Netherlands.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
In a Phase IIb study, data showed that Prota Therapeutics' oral immunotherapy led to 51% of children reaching clinical remission of their peanut allergy compared to placebo. See inside for this and more!
-
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
5/12/2022
Affimed N.V. announced an upcoming poster presentation demonstrating the cytotoxic potential of its CD123/CD16A-targeting innate cell engager AFM28 at the Annual Meeting of the European Hematology Association to be held in Vienna, Austria on June 9 - 12, 2022.
-
Affimed Provides Update on ASCO AFM13-104 Oral Presentation
5/6/2022
Affimed N.V. announced that the American Society of Clinical Oncology has informed the Company’s collaborator that it has removed the previously announced oral presentation on AFM13-104, the investigator sponsored trial that evaluates AFM13 pre-complexed with NK cells in patients with relapsed/refractory CD30-positive lymphomas, from the upcoming conference program.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
4/13/2022
Affimed N.V. announced the pricing of its previously announced public offering of 22,500,000 of its common shares at a public offering price of $4.00 per common share.
-
Cytovia could become the first company to use a combination of natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) and NK engager antibodies to treat solid tumors.
-
Affimed Announces Proposed Public Offering of Common Shares - Apr 12, 2022
4/12/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it has commenced an underwritten public offering of common shares.
-
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
-
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting
4/10/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, provided a data update from the ongoing study of the Company’s lead innate cell engager AFM13 precomplexed with cord blood-derived natural killer cells.
-
Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress
3/31/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the year ended December 31, 2021, and provided an update on clinical and corporate progress.
-
Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022
3/24/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release full year 2021 results and corporate update on Thursday, March 31, 2022.
-
Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers after Freezing & Thawing
2/9/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced the publication of pre-clinical data demonstrating the cytotoxic potency and efficacy of NK cells precomplexed with ICE® molecules after one cycle of cryopreservation.